

**Statement of Unaudited Standalone Financial Results for the Nine Months and Third Quarter Ended on 31/12/2018**

Rs. In Lacs other than EPS

Sr. No.	Particulars	Quarter Ended			Year to Date		Previous Year Ended
		31/12/2018	30/09/2018	31/12/2017	31/12/2018	31/12/2017	31/03/2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	3227.58	3198.44	3087.44	8751.84	8461.60	11467.42
2	Other Income	66.72	90.48	69.23	247.73	274.59	339.40
3	<b>Total income</b>	<b>3294.30</b>	<b>3288.92</b>	<b>3156.67</b>	<b>8999.57</b>	<b>8736.19</b>	<b>11806.82</b>
4	<b>Expenses</b>						
	(a) Cost of Materials Consumed	475.9	225.53	257.14	950.39	649.26	986.21
	(b) Purchase of Stock-in-trade	653.93	688.03	822.66	1910.70	1670.21	2064.62
	(c) Changes in inventories of Finished Goods, Stock-in-trade and WIP	-159.40	77.90	-87.39	-189.68	294.91	348.29
	(d) Employee benefit expenses	794.58	725.58	726.97	2298.66	2095.56	2769.18
	(e) Finance Costs	10.70	9.28	11.10	28.97	28.57	41.21
	(f) Depreciation and Amortisation Expense	35.31	33.21	37.63	100.14	111.81	150.02
	(g) other expenses	825.78	773.12	722.21	2176.27	2223.53	2920.40
	<b>Total Expenses</b>	<b>2636.80</b>	<b>2532.65</b>	<b>2490.32</b>	<b>7275.45</b>	<b>7073.85</b>	<b>9279.93</b>
5	<b>Profit before exceptional items &amp; Tax</b>	<b>657.50</b>	<b>756.27</b>	<b>666.35</b>	<b>1724.12</b>	<b>1662.34</b>	<b>2526.89</b>
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
7	<b>Profit before tax</b>	<b>657.50</b>	<b>756.27</b>	<b>666.35</b>	<b>1724.12</b>	<b>1662.34</b>	<b>2526.89</b>
8	<b>Tax Expense</b>						
	(i) Current Tax	200.00	195.00	215.00	500.00	515.00	830.00
	(ii) Income Tax for previous years	-4.72	0.00	0.00	-37.52	0.00	14.24
	(ii) Deferred Tax	15.98	-13.11	-2.73	-28.69	-16.10	-38.57
9	<b>Profit after tax for the period</b>	<b>446.24</b>	<b>574.38</b>	<b>454.08</b>	<b>1290.33</b>	<b>1163.44</b>	<b>1721.22</b>
10	<b>Other Comprehensive Income</b>						
	(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	-97.99
	(ii) Income Tax relating to Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(iii) Items that will be reclassified to profit or loss	8.93	-7.67	6.87	8.79	27.58	27.60
	(iv) Income Tax relating to Items that will be reclassified to profit or loss	-1.52	1.43	0.00	-12.20	0.00	-0.03
11	<b>Total Comprehensive Income for the period</b>	<b>453.65</b>	<b>568.14</b>	<b>460.95</b>	<b>1286.92</b>	<b>1191.02</b>	<b>1650.80</b>
12	<b>Paid up Equity Share Capital (F.V. Rs.10/- each)</b>	<b>458.94</b>	<b>458.94</b>	<b>458.94</b>	<b>458.94</b>	<b>458.94</b>	<b>458.94</b>
13	<b>Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted</b>	<b>9.72</b>	<b>12.52</b>	<b>9.89</b>	<b>28.12</b>	<b>25.35</b>	<b>37.50</b>

**Notes:**


- The Company has adopted Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act 2013, read with relevant rules issued there under from 1<sup>st</sup> April, 2017 and accordingly, these standalone unaudited financial results (including figures for the previous quarters and year ended 31<sup>st</sup> March, 2018) have been prepared in accordance with the recognition and measurement principles laid down in Ind AS.
- The above statement of unaudited standalone financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 5<sup>th</sup> February, 2019.

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

- 3 The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- 4 The figures of the previous year/period have been regrouped/recast/rearranged to render them comparable with figures of the current period.

**Place : Mumbai****Date : 05<sup>th</sup> February, 2019**

By order of the Board  
For Jenburkt Pharmaceuticals Ltd.

  
(ASHISH U BHUTA)  
CHAIRMAN AND MANAGING DIRECTOR





# D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9<sup>TH</sup> FLOOR, TARDEO CIRCLE, MUMBAI –  
400034. TEL: 23513758 / 23520330, 9322508373

Email ID: [info@drmehta.in](mailto:info@drmehta.in), [vikram@drmehta.in](mailto:vikram@drmehta.in), [ashok@drmehta.in](mailto:ashok@drmehta.in)

Review Report to  
The Board of Directors

Jenburkt Pharmaceuticals Ltd.

We have reviewed the accompanying statement of unaudited financial results of Jenburkt Pharmaceuticals Ltd. for the quarter ended 31<sup>st</sup> December 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D R Mehta & Associates  
Chartered Accountants  
(FRN. 106207W)



Signature  
Ashok Mehta  
Partner  
(M. No.: 101746)



ASHOK D. MEHTA  
M. NO. 101746

Place: Mumbai  
Date: 5<sup>th</sup> February, 2019